




   MODULATION OF GUT IMMUNE AND HOST 




   By 
LAWRANCE CHRISTOPHER CHANDRA 
   Bachelor of Veterinary Science (Veterinary Medicine) 
   Tamil Nadu Veterinary and Animal Sciences University 
   Chennai, Tamil Nadu, India 
   1996 
 
   Master of Veterinary Science (Pharmacology) 
   Tamil Nadu Veterinary and Animal Sciences University 
   Chennai, Tamil Nadu, India 
   1999 
 
 
   Submitted to the Faculty of the 
   Graduate College of the 
   Oklahoma State University 
   in partial fulfillment of 
   the requirements for 
   the Degree of 
   DOCTOR OF PHILOSOPHY 




      MODULATION OF GUT IMMUNE AND HOST 






   Dissertation Approved: 
 
   Dr. Solo Kuvibidila 
  Dissertation Adviser 
   Dr. Brenda J Smith 
 
   Dr. Stephen L Clarke 
Dr. Do’ffay M Jean 
 
   Dr. Denver Marlow 
  Outside Committee Member 
  Dr. Mark E. Payton 




TABLE OF CONTENTS 
 
Chapter          Page 
 
I. INTRODUCTION ......................................................................................................1 
 
 Introduction ..............................................................................................................1 
 Hypothesis..............................................................................................................10 
 Objectives ..............................................................................................................10 




II. REVIEW OF LITERATURE..................................................................................13 
  
 Gut immune system: structure and function ..........................................................13 
 IL23/IL17 axis in gut immunity .............................................................................15 
 Dentritic cells .........................................................................................................16 
 Mushrooms health benefits in general ...................................................................18 
      Eritadenine .............................................................................................................20 
 Mushrooms and dendritic cell biology ..................................................................20 
 Animal models of intestinal inflammation ............................................................22 
 Cytokines and intestinal inflammation ..................................................................26 
 Mushrooms and inflammation ...............................................................................27 
 Mushrooms and intestinal inflammation ...............................................................29 
 β-glucans on immunity and inflammation .............................................................30 
      Non alcoholic fatty liver disease (NAFLD) ...........................................................32 
      Animal models of NAFLD ....................................................................................33 
      Cytokines and NAFLD ..........................................................................................34 
       
 
III. Manuscript-1 ..........................................................................................................36 
 
 Abstract ..................................................................................................................37 
 Introduction ............................................................................................................40 
 Materials and Methods ...........................................................................................42 
 Results ....................................................................................................................45 
 Discussion ..............................................................................................................48 







                     Page 
 
IV. Manuscript-2 ..........................................................................................................63 
 
 Abstract ..................................................................................................................65 
 Introduction ............................................................................................................66 
 Materials and Methods ...........................................................................................68 
 Results ....................................................................................................................70 
 Discussion ..............................................................................................................71 
      References ..............................................................................................................75 
 
V.  CONCLUSION ......................................................................................................84 
 
 Conclusion .............................................................................................................84 
  
VI. RECOMMENDATIONS FOR FUTURE RESEARCH .......................................86 
 




















LIST OF TABLES 
 
 
Table           Page 
 
   1 Composition of study diets ....................................................................................78 
   2 Effect of different diet on body weight, food intake, liver weight  




LIST OF FIGURES 
 
Figure           Page 
 
   1 Effect of dietary treatment on final body weight and thymus weight....................55 
   2 Effect of mushroom supplementation on plasma IL-23 with or without DSS  
      challenge ................................................................................................................56 
   3 Effect of mushroom supplementation on plasma IL-6 levels ................................57 
   4 Effect of mushroom supplementation on IL-6 secretion by spleen cells ...............58 
   5 Effect of mushroom supplementation on colon MPO concentration and length ...59 
   6A Effect of mushroom supplementation on colon histology ..................................60 
   6B Effect of mushroom supplementation on colon inflammation score ..................61 
   7 Effect of mushroom extracts on in vitro IL-23 secretion by the murine J.744.1. ..62 
 
 
   1 Effect of control, SM and WBM supplemented diet on  
      liver histology and histochemistry .........................................................................80 
   2 Effect of control, SM and WBM supplemented diet on fatty liver scores 
      in C57BL/6 mice ....................................................................................................81 
   3 Effect of SM withdrawal from the diet showing liver histology and  
      the effect of SM supplemented diet showing normal heart and kidney histology .82 









Infectious diseases like plague, leprosy, and small pox have been known to exist in 
ancient times and devastate the human population during pandemic outbreaks. Although 
there has been a sharp decline in the prevalence of several infectious diseases caused by 
bacteria, viruses and parasites after the introduction of modern chemotherapeutic agents, 
infectious diseases still remain a major public health problem worldwide due to emerging 
new pathogens that are resistance to chemotherapy (Herrera LA et al 2005).   
Currently, it is estimated that at least 6 billion people around the world are infected with 
any one of the known infectious agents including bacteria, viruses and parasites (Mazza 
JJ 2010). These pathogenic organisms cause acute and/or chronic infectious diseases in 
susceptible or vulnerable populations. Acute infectious diseases like dengue, bacterial 
meningitis, septicemia, and cerebral malaria cause significant mortality whereas chronic 
infectious diseases devastate the economy due to long term medical care and reduction in 
man power (Herrera LA et al 2005).   
Moreover, there is a strong relationship between certain chronic infectious diseases and 




(Parkin DM 2006).Twenty percent of human cancers are directly attributed to infectious 
agents (Mazza JJ 2010). The worldwide increase in morbidity and mortality rates due to 
cancer cancer  which is the second leading cause of death in the USA (CDC), pose not 
only challenges to medical professionals but also cause significant economic burden to 
the nations (WHO).  
Although the etiology for each infectious disease may be different, inflammation is the 
key event in all infectious diseases (Robbins 2004). Inflammation is defined as the 
complex biological response of vascularized living tissues to harmful stimuli (Robbins 
2004). Several immunological factors including cytokines, chemokines, cell adhesion 
molecules and antimicrobial peptides contribute to the pathophysiology of inflammation 
(Robbins 2004). Inflammation can be broadly classified into two categories, namely 
acute and chronic inflammation (Dinarello CA 1997). Acute inflammation is an 
immediate immune mediated defensive response for any noxius stimuli, which usually 
lives only a few hours to a few days (Dinarello CA 1997). In contrast, chronic 
inflammation is an unwanted inflammatory response that sustains for months to years. 
Neutrophils are the primary immune cells involved in acute inflammation to defend 
against pathogens by releasing antimicrobial chemicals such as peroxides, lysozymes and 
defensins (Doherty NS & Janusz MJ 1994). Mononuclear leukocytes, including 




section from chronic inflammation. Unlike acute inflammation, chronic inflammation has 
been linked to many chronic diseases, including (Santos MJ et al 2009). 
Cytokines are the multifunctional and pleiotrophic molecules involved in inflammation 
cascades. Some cytokines are proinflammatory, whereas others are anti-
inflammatory/regulatory in nature. Imbalance between these two categories of cytokines 
has been implicated in the pathogenesis of infectious diseases and cancer (Sanchez-
Munoz F et al 2008). Defensins are the natural antimicrobial peptides active against 
pathogenic bacteria, fungi, and some enveloped viruses (Ramasundara M et al 2009). 
Leukocytes and epithelial cells are the major sources of defensins.  
Defensins play many roles in the immune response including both indirect and direct 
antimicrobial activity, the ability to act as chemokines as well as induce chemokine 
production leading to recruitment of leukocytes to the site of infection and the promotion 
of wound healing (Ramasundara M et al 2009). Defensins such as α-defensins and β-
defensins confer not only innate immunity, but also link innate immunity to adaptive 
immunity. Defective defensin production and secretion has been directly implicated in 
gastrointestinal (GI) tract diseases such as inflammatory bowel disease (Ramasundara M 
et al 2009). 
The GI tract represents the largest mucosal surface in the body which makes it critical as 
most pathogens (90%) enter into the body through mucosa (Nagler-Anderson C 2001, de 




in digestion and absorption of essential nutrients into our body but also offers protection 
against various pathogens through the GI immune system (Shale M 2010 and Hisamatsu 
T et al 2008). The GI immune system consists of mesenteric lymph nodes, Peyer’s 
patches and lamina propria associated lymphocytes (Mowat AM 2003). The GI immune 
system has the constant challenge of responding to pathogens and toxins without 
responding to food antigens or the commensal microflora (Mowat AM 2003). Both of 
these challenging tasks are simultaneously performed by dendritic cells (DCs), the 
professional antigen presenting cells present in GI tract.  
DCs orchestrate a repertoire of immune responses such as differentiation of naive T cells 
and initiate primary immune responses that provide resistance to infection and tolerance 
to self. (Ralph M 2007 and Sato K 2007). Although some microbes and tumors may hide 
from dendritic cells to evade immunity, DCs can be activated to recognize these 
camouflaged microbes and cancer cells by DC-targeted bioactive molecules. (Ralph M 
2007). In addition, cytokines produced by the DCs is critical in determining the 
polarization of the helper T cell responses such as Th1 or Th2 or Th17 (Banchereau J 
2000, Ardavín C 2004 and Yu CF 2010).  
Hence, it is not surprising that cytokines produced by the intestinal dendritic cells play a 
major role in GI immune system (Perdigón G 2002). Although several cytokines 
produced by gastro intestinal DCs are involved in mucosal defense against pathogens, IL-




in GI mucosa (Ciccia F 2009, Doisne JM 2010 & Brereton CF 2011). Therefore, 
bioactive molecules modulating DCs induced IL-23 cytokine secretion and regulation 
might be a novel approach in promoting gut immunity and treating diseases (Harada N 
2003, Tacken PJ 2005 and Ralph M 2007). 
IL-23 is involved in the differentiation of naive CD4+ T cells into Th17 cells (Maloy KJ 
et al 2008) in combination with IL-6 and TGF-β1. These Th17 cells secrete IL-17 
cytokine that is involved in the defense against pathogens by recruiting neutrophils to the 
site of inflammation (McAleer JP et al 2011). Further, the IL-23/IL-17 axis plays a major 
role in regulating intestinal inflammation and defensin production (Uhlig HH 2006). 
Therefore, IL-23/IL-17 axis is involved in destroying most GI pathogens, including 
Vibrio cholera, E. coli and Salmonella (Doisne JM et al 2010). Moreover, IL-23 also 
increases immunological memory by inducing CD4+ T memory cells’ proliferation. 
Hence, increasing the mucosal IL-23 production is one of the novel strategies in 
improving mucosal immunity/immunological memory (Agrawal S et al 2010).  
Although most GI tract infections have been eradicated in developed countries, 
Salmonellosis, Campylobacteriosis, E. coli infections, listeriosis, and Cholera remain 
major public health problems (Meyer C 2010 and de la Cabada 2011). Several antibiotics 
have been developed to treat GI tract infections; still there is a search for alternatives to 
these antibiotics due to the emergence of antibiotic resistant bacteria (DuPont HL 2005). 




leading to intestinal dysbiosis. This intestinal dysbiosis is now believed to be a 
contributing factor to many chronic and degenerative diseases such as irritable bowel 
syndrome, inflammatory bowel disease, rheumatoid arthritis, and ankylosing spondylitis 
(Hawrelak JA 2004).  
One alternative to antibiotic treatment is to increase the production of endogenous 
antimicrobial peptides including defensins by using natural compounds or functional 
foods (Cunliffe RN 2003 &Wehkamp J 2005). In this regard, several mushrooms have 
emerged as a functional food to stimulate innate and adaptive immunity.  
Mushrooms are rich in fibers, beta glucan, and some essential micronutrients such as Se, 
Zn and Fe (Raymond Chang 1997). Currently, there are about 700 species of edible 
mushrooms being known to the world (Chang and Miles 2004). However, only handful 
of mushrooms such as white button (WBM), portabella (PM) and shiitake (SM) 
mushrooms has been marketed to the consumers (Raymond Chang 1997). Interestingly, 
the production of Agaricus mushrooms, including white button mushroom and portabella 
mushroom has increased throughout the world (USDA). The top ten countries producing 
Agaricus mushrooms are China, USA, Netherlands, France, Poland, Italy, Spain, Ireland, 
United Kingdom and Germany (USDA). Currently, the USA is the second largest 
producer of Agaricus mushrooms in the world. Further, the consumption of Agaricus 





Next to Agaricus mushrooms, SM is the second most cultivated edible mushrooms 
comprising about 25% of the worldwide production (Jiang T et al 2010). SM is an edible 
exotic mushroom scientifically known as Lentinula edodes native to China and cultivated 
in East Asia (Raymond Chang 1997). SM was considered a royal food in ancient times 
due to its nutritive value, delicacy and scarcity. Although SM had been cultivated mainly 
by traditional methods in East Asian countries, the advancement of mushroom production 
and biotechnology led to large scale commercial cultivation of SM worldwide (Chang 
and Miles 2004). Interestingly, the SM production has exceeded more than 9 million 
pounds per annum during 2009 in United States (USDA). Because of their widespread 
availability and significant reduction in price, the consumption of SM has been increased 
in recent years. Both fresh and dried forms of SM have been used in many East Asian 
cuisines for many years and have been slowly entering its way into Western cuisine in 
recent years (Chang and Miles 2004). Although both forms of SM are used for culinary 
purpose, many people prefer the dried form of SM due to its flavor and vitamin D 
content. Hence, SM is often sold as dried powder for commercial use. Moreover, crude 
and purified extracts from SM have been used in complementary and alternative 
medicine (CAM) therapy to treat immunodeficiency associated with viral infections and 
cancer (Raymond Chang 1997).  
Some of the medicinal mushrooms such as maitake, shiitake, chaga, and reishi have been 
scientifically evaluated for their health benefits unlike Agaricus mushrooms. Moreover, 




evaluate their effects rather than the culinary forms of whole mushrooms. Further, there 
is a paucity of data on the effect of WBM and portabello PM mushrooms, the most 
commonly consumed mushrooms in the World including United States. Previous report 
from our lab showed that the extracts from edible mushroom enhance α-defensin 
production in HL60, a human promyelocytic cell line (Kuvibidila S and Korlagunta 
2009). Since IL-23/IL-17 axis is involved in the production of defensins in gut mucosa, 
we studied the effect of white button (WBM) and portabello (PM) mushrooms on IL-23 
secretion both in-vitro and in-vivo models for this study. To the best of our knowledge 
this is the first study in investigating the effect of WBM and portabello PM mushrooms 
on IL-23 and gut immunity in general (Borchers AT 2008).  
Although functional foods including mushrooms are gaining much attention in food and 
nutrition field, the term functional foods has no legal meaning in United States (ADA 
2009). This is due to lack of scientific literature regarding the health benefits and safety 
issues associated with these functional foods (ADA). Therefore, the American Dietetic 
Association (ADA) supports “research to further define the health benefits and risks of 
individual functional foods and their physiologically active components.” Surprisingly 
the edible wild mushroom Tricholoma equestre caused a rare toxicity called 
rhabdomyolysis in humans when they ate large quantities of these mushroom (Bedry R et 
al 2001). Once this report appeared in the New England Journal of Medicine in 2001, the 
need for examining the risk associated with edible mushrooms became imperative----. In 




mg/mouse/day) for 5 days caused significant increase in plasma creatine kinase level. 
This study further supports the need for examining safety evaluation of edible 
mushrooms for long term consumption. Moreover, there is not much information about 
the adverse effects of Agaricus and Shiitake mushrooms.  
Surprisingly, we observed that fortification of the AIN93 diet with 5% lyophilized SM 
was associated with a two fold increase in plasma interleukin-6 (IL-6) in DBA mice with 
collagen-induced arthritis (Lawrance Chandra et al 2010). Since IL-6 is thought to be 
implicated in the pathogenesis of fatty liver disease (Mclaine et al 2004), we reviewed the 
literature regarding the association between consumption of edible mushrooms and risk 
of non-alcoholic fatty liver disease (NAFLD) is a disorder of lipid metabolism 
characterized histologically by hepatic steatosis in the absence of excessive alcohol 
consumption (James et al 2010).  However, we did not find much information related to 
SM and NAFLD.  
NAFLD has drawn much attention due to its intimate association with insulin resistance, 
metabolic syndrome, cirrhosis, and end stage liver failure (James et al 2010). Moreover, 
NAFLD has emerged as a major public health problem in recent years (James et al 2010). 
Surprisingly, the prevalence of NAFLD in adult Japanese population with normal body 
mass index (BMI) was 29% which is very high compared to Western population (Jimba 
et al 2005). Among East Asian countries, the prevalence of NAFLD in the population 




the world (James et al 2010). Therefore we investigated the effect of supplementation of 
the AIN93 diet with dry-lyophilized SM powder on fatty liver prevalence in C57BL/6 
mice. To the best of our knowledge, this is the first study to evaluate chronic 
consumption of Agaricus mushrooms and Shiitake mushrooms on fatty liver 
development.  
We performed two studies to test our hypotheses. 
Hypothesis for study-1: a. Edible mushroom supplementation may enhance gut 
immunity/inflammation by up-regulating IL-23 production in the gastrointestinal tract 
and less so in peripheral lymphoid organs such as spleen. b. Edible mushrooms up-
regulate IL-23 through dectin-1 pathway.   
Objectives 
1. To evaluate the effect of edible mushrooms on IL-23 secretion in DSS treated and 
untreated mice 
2. To evaluate the effect of edible mushrooms on IL-6 secretion in DSS treated and 
untreated mice 
3. To evaluate the effect of edible mushrooms on neutrophil infiltrations and 
myeloperoxidase level  
4. To delineate the molecular mechanism by which edible mushrooms up-regulates 





Hypothesis for study- 2: Chronic consumption of edible mushrooms specifically, Shiitake 
mushroom will cause fatty liver. 
Objectives 
1. To study the effect of 5% edible Shiitake mushroom fortified diet on the 
prevalence of fatty liver in C57BL/6 mice.  
2. To characterize the Shiitake mushroom-induced fatty changes in the liver and 
other vital organs  
Study limitations 
In our study-1, we neither isolate mouse dendritic cells from our mice nor do we perform 
any immunohistochemical procedures to localize these dendritic cells in the GI tract of 
these mice. Moreover, we did not study other closely related cytokines such as IL-17, IL-
22, which are also involved in the up-regulation of defensin.  In addition, we did not 
challenge these mice with known GI pathogens such as Salmonella, E. coli to see the 
protective effect of mushroom induced IL-23 up-regulation. Furthermore, we did not 
perform mucosal vaccine titer response to translate the IL-23 induced immunological 





The major weakness of our study-2 is the lack of mechanistic approach to investigate 
how these SM caused fatty liver by using hepatocyte cell lines. Moreover, we did not 
have mice group fed with pure form of eritadenine, a phytochemical rich in SM. This 
approach would have helped us to explain some mechanism responsible for fatty liver 
development. In addition we did not study the dose and time response of SM in fatty liver 
development.  Finally, we did not study the expressions of genes involved in liver fat 
synthesis.  
Lastly, the demerits with any animal or pre-clinical study, we cannot directly extrapolate 








Gut immune system: Structure and function 
Gut immune system is composed of extrinsic and intrinsic barriers with non-specific and 
specific defense mechanisms (James SP 1993).  Extrinsic barriers include gastrointestinal 
acidity, digestive enzymes, mucus, peristalsis, and an immunological which provides a 
source of secretory IgA and IgM (James SP 1993 and Langkamp-Henken B et al 
1992).The  intrinsic barriers of gut immune system consist of aggregated and 
nonaggregated lymphoid follicles known as gut associated lymphoid tissues (James SP 
1993 and Langkamp-Henken B et al 1992). These elements of the gut immune system 
function together to generate an immune response against harmful pathogens and to 
generate tolerance against dietary antigens and normal microbial flora (Langkamp-
Henken B et al 1992). Therefore, intestinal mucosa forms a tight barrier not only against 
invading pathogens but also against dietary antigens and commensal bacteria. However, 
these tight mucosal barriers allow transport of nutrients across the epithelium. The 
integrity of both the intrinsic and extrinsic barriers may be influenced by environmental 
factors such as diet, microbes and genetic composition. Uncontrolled entry of pathogens 
through the gut mucosa cause not only gastointestinal infections, but also other systemic 
bacterial and viral diseases (James SP 1993 and Langkamp-Henken B et al 1992).  
Gut immune system is distinct from other immune systems in many ways:  i) presence of 




are initiated; ii) mucosal homing of lymphoid cells, a relatively specific recirculation of 
lymphoid cells to the mucosa; iii) IgA producing B cells and memory T cells are 
predominate at mucosal surfaces and the secretory IgA is the major mucosal 
immunoglobulin. These features make gut immune system a unique immune system in 
the body (McGhee JR et al 2007 and Suzuki K et al 2010). 
The gut immune system protects the intestinal mucosa from invading pathogens by the 
network of immune cells including B-cells, T-cells, macrophages and dendritic cells 
present in the mucosa (Suzuki K et al 2010). A majority of the lymphocytes are found in 
Peyer´s patches, mesenteric lymph nodes (MLN) and scattered throughout the lamina 
propria and mucosal epithelium. The lamina propria contains large numbers of B-cells, 
plasma cells, macrophages, dendritic cells, and T-cells of both CD4+ and CD8+ subsets. 
Lymphocytes present within the intestinal mucosal epithelium are known as 
intraepithelial lymphocytes (IELs). It is estimated that 10 to 15% of the cells in the 
intestinal mucosal epithelium are IELs. It is also known that CD8+ T-cells constitute the 
major cells in intraepithelial lymphocytes population. These CD8+ T-cells express γδ-
TCR (<10% in the small intestine, 40% in the colon in humans), which is yet another 
distinct feature of IELs. These γδ-TCR expressing CD8+ T-cells were increased in 
patients with active celiac disease or food allergy (Savilahti et al 1990) 
Antigen presentation in the gut immune system is a complex process, carried out by 
professional APCs or by specialized epithelial cells known as M cells. After activation in 
the gut immune system, lymphocytes up regulate α4β7-integrin, a lymphocyte adhesion 
molecule (Hart AL et al 2010). This lymphocyte adhesion molecule helps to recirculate 




mucosal vascular addressin molecule (Hart AL et al 2010). Interestingly, IELs expressing 
α4β7-integrin are believed to reside within the intestinal mucosa permanently (Hart AL et 
al 2010). Cross-talk between epithelial cells and the mucosal lymphocytes is critical for 
the induction of tolerance and expression of active mucosal immunity. Under 
normal/physiological conditions, antigen-presenting epithelial cells do not express co-
stimulatory molecules (Arnett HA and Viney JL 2010). Therefore, antigen-presentation 
by epithelial cells leads to tolerance. However, under pathological conditions 
(inflammatory or infectious), activation of IELs occurs due to the expression of 
costimulatory molecules by the APCs (Arnett HA and Viney JL 2010). 
IL-23/IL-17 axis in gut immunity 
IL-23 is a cytokine produced primarily by activated DCs and macrophages and to some 
extent by paneth cells (Doisne JM 2010 & Ciccia F 2009). IL-23 is a heterodimeric 
cytokine related to IL-12 sharing a p40 sub unit (McKenzie BS et al 2006). Although 
both cytokines poss a strong structural relationships, these similarities not translate into 
functional similarity (Oppmann B 2000). In fact, these two cytokines appear to have 
profoundly different roles in regulating the host immune responses (Oppmann B 2000).  
Hue S et al 2006 observed that IL-23p19 was predominantly expressed in the intestinal 
mucosa rather than mesenteric LN (MLN) or spleen. These suggest that IL-23 might have 
primary role on gut mucosal immunity and inflammation (Hue S et al 2006).  
In conjunction with IL-6 and TGF-β1, IL-23 stimulates naive CD4+ T cells to 
differentiate into a novel subset of cells called Th17 cells (Maloy KJ 2008). Moreover, it 
is required for the expansion and survival of Th17 cells that are important in intestinal, 




IL-17, which is involved in the primary and first line of defense against pathogens by 
recruiting neutrophils to the site of inflammation (McAleer JP 2011). Further, the IL-
23/IL-17 axis plays a major role in local intestinal inflammation and production of 
defensin in gut mucosa (Uhlig HH 2006).  
Defensins are short chain antimicrobial peptides with three characteristic pairs of 
intramolecular disulfide bonds and a β-sheet structure (Guaní-Guerra E et al 2010) . 
Defensins are classified into three major groups namely α, β and θ-defensins according to 
the arrangement and spacing of the disulfide bonds (Guaní-Guerra E et al 2010). Paneth 
cells, located at the base of intestinal crypts, are the major source of defensins in the 
intestinal mucosa (Bevins CL 2005). These defensins play major role in gut innate 
immunity (Bevins CL 2005).  
Because of the IL-23/IL-17 axis is involved both directly and indirectly in destroying 
most GI pathogens, including Vibrio cholera, E. coli and Salmonella (Doisne JM 2010). 
IL-23 also promotes immunological memory by stimulating CD4+ T memory cells 
proliferation. Hence, increasing mucosal IL-23 production might improve mucosal 
immunity/immunological memory (Agrawal S 2010). Moreover, IL-23 augmented 
vaccine- induced tumor-specific CD8+ T cell responses against murine melanoma 
(Overwijk WW et al 2006). 
Dendritic cells 
Dendritic cells (DCs), recognized as professional antigen presenting cells, orchestrate a 
repertoire of immune responses including the differentiation of naive T cells and the 




tolerance to self. (Ralph M 2007 & Sato K 2007).  DCs are formed from either myeloid 
or lymphoid bone marrow progenitors via intermediate DC precursors that arrive at sites 
of potential pathogen entry, where they differentiate locally into immature DCs. (Ardavín 
C 2004). These immature DCs undergo a complex maturation process when they capture 
antigen in the presence of danger signals associated with inflammation or infection.  
However, antigen capture alone in the absence of activation stimuli will not lead to 
maturation. The net result, in the absence of co-stimulatory signal molecules, such as 
CD40, CD54, CD83, B7.1 and B7.2 (CD80 and CD86), immature DCs presents antigen 
to the T cells that lead to T cell tolerance. Therefore, the mature DCs act as sentinels in 
recognizing microbes and tumors by capturing and transferring these antigens to the cells 
of the adaptive immune system thereby regulates the types of T cell immune responses. 
(Sato K 2007). Although microbes and tumors escape from these sentinel dendritic cells 
to evade immunity, DC can be activated to recognize those camouflaged microbes and 
cancer cells by DC-targeted bioactive molecule. (Ralph M 2007). Similarly, DC-targeted 
bioactive molecules can be used to silence DCs instigated unwanted autoimmune 
responses (Ralph M 2007). 
Moreover, the cytokines produced by the DCs are critical in determining the polarization 
of the helper T cell responses such as Th1 or Th2 or Th17 (Banchereau J 2000, Ardavín 
C 2004 and Yu CF 2010). Th1 cell mediated immune responses targeted towards 
intracellular pathogens through the production of interferon gamma (IFN-γ) and IL-2.  
On the other hand, Th2 humoral immune response occurs through the production of IL-4, 
IL-5, IL-6, and IL-13. Interestingly, Th17 response targeted primarily bacterial and 




DC-produced IL-12 is critical in the generation of a Th1 immune response whereas IL-23 
produced by DCs is critical for Th17 response (Banchereau J 2000, Ardavín C 2004 and 
Yu CF 2010). Similarly, DC- produced anti-inflammatory cytokines such as IL-4, IL-10 
are crucial in Th2 and Treg responses. Therefore bioactive molecules targeting DCs 
biology and cytokines regulation are the emerging translational approach in preventing 
and treating illness (Harada N 2003, Tacken PJ 2005 and Ralph M 2007). 
Mushroom health benefits in general 
White Button Mushroom 
White button mushrooms (Agaricus bisporus) belong to the genus Agaricus and are 
widely consumed in the world. They represent about 90% of mushrooms consumed by 
Americans. However, the health benefits of this strain in general are not well studied. Wu 
et al (2007) reported the immunomodulatory effects of white button mushroom by 
enhancing the natural killer cell activity. White button mushrooms are known to inhibit 
aromatase, an enzyme involved in the conversion of androgen to estrogen, thereby 
suppressing breast cancer cell proliferation in vitro (Chen S et al 2006). Further Yu et al 
showed mild protective effects of white button mushroom in dextran sodium sulfate 
(DSS) induced colitis mouse model (Yu S et al 2009), though the molecular mechanism 
by which WBM alters the immune response remains to be elucidated. 
Portobello mushroom 
Portobello mushroom belongs to the same species Agaricus bisporus as the WBM; 
however, portobello mushrooms are different from white button mushroom in terms of 




button mushrooms, portobello mushrooms are also consumed widely around the world. 
However, to date there are no studies related to health benefits of dietary supplementation 
of portobello mushroom found in the scientific literatures. 
Shiitake Mushroom 
Shiitake mushroom (Lentinula edodes) is an edible mushroom consumed in Asian 
countries mainly Japan, China, Korea and Thailand. Lentinus edodes is the second most 
popular edible mushroom in the global market due to its medicinal properties and 
nutritional value (Bisen PS 2010). Lentinan, lectins and eritadenine are some of the 
bioactive compounds isolated from SM. (Bisen PS 2010). Unlike other mushrooms, SM 
has high concentration of eritadenine which exibits hypocholesterolemic properties. 
Lentinan, the polysaccharides found in SM consists of a beta-1,6-branched-beta-1,4-
glucan linkage (Lee HH 2009). Lentinan was shown to increase the phagocytic activity of 
macrophages by up-regulating inflammatory cytokines. (Lee HH 2009). Lentinen was 
also known to have anti-tumor effect through activation of NK cells and macropahges 
(Kataoka H 2009). In a fish model, lentinen reduced the expression of genes involved in 
acute inflammatory reactions suggesting species difference in the response (Djordjevic B 
2009). Antimicrobial activities of shiitake mushroom against pathogenic bacteria and 
fungi have recently been documented (Rao JR et al 2008). Shiitake mushroom boosted 
the BCG vaccine response in guinea pigs by activation of alveolar macrophages 







Eritadenine, an adenosine compond responsible for hypocholesterolemic effects of 
Shiitake mushroom (Kaneda T and Tokuda S 1966). Eritadenine also known as lentinacin 
has been shown to reduce cholesterol levels in rats by 25% after 7 days of feeding 
eritadenine supplemented (0.005%) diet (Chibata I et al 1969). The hypocholesterolemic 
action of eritadenine is due to a modification of the hepatic phospholipid metabolism by 
inducing a phosphatidylethanolamine N-methyltransferase enzyme deficiency (Sugiyama 
K et al 1995). Further, dietary eritadenine altered the fatty acid profile of liver by 
suppressing the metabolic conversion of linoleic acid into arachidonic acid (Sugiyama K 
& Yamakawa A 1996, Sugiyama K et al 1997a and 1997b).  It is also shown that 
eritadenine suppress the Δ6-desaturase activity through transcriptional regulation 
(Shimada Y et al 2002). Dietary eritadenine supplementation counteracted the 
hyperhomocysteinemic effect of guanidinoacetic-acid in rats (Fukada et al 2006). 
Mushrooms and dendritic cell biology  
In vivo study using C3H/HeJ mice, intraperitoneal administration of polysaccharide 
obtained from Grifola frondosa stimulates dendritic cells to produce IL-12 and IL-10 
production (Kodama N J 2004). This Grifola frondosa induced IL-12 cytokines enhanced 
NK cell cytotoxicity against MM-46 mammary tumor in C3H/HeJ mice (Kodama N J 
2005). Similar results were observed when low-molecular-weight protein fractions of the 
maitake mushroom administered in colon-26 carcinoma-bearing mice by the same 
research group. (Kodama N J 2010).  Interestingly,  a novel heteropolysaccharide maitake 
Z-fraction (MZF) from the maitake mushroom, upregulated the markers of dendritic cell 




on bone marrow-derived dendritic cells (DCs) in BALB/c mice. In addition to this, 
maitake Z-fraction also increased the IL-12 and TNF-α production by DCs (Masuda Y 
2010). Therefore it is clear that maitake mushrooms are capable of stimulating DC 
towards a Th1 response. However, the effect maitake mushrooms on Th17 pathway is 
still unknown.  
Proteoglycan isolated from Phellinus linteus up-regulated the phenotypic and functional 
maturation markers such as major histocompatibility complex (MHC) class II and CD86 
in murine bone marrow-derived dendritic cells. (Kim GY 2004). This proteoglycan 
activated DCs via TLR2 and/or TLR4 mediated-NFkB, ERK and p38 MAPK signal 
pathways. (Kim GY 2004b). Further, proteoglycan isolated from Phellinus linteus 
suppressed tumor growth in vivo through DC activated Th1 type immune response that 
lead to enhanced CD8+ response (Kim GY 2004a). In a recent study, extract from 
Phellinus linteus augmented mucosal vaccine induced immune response against H5N1 
influenza A in mice (Ichinohe T 2010). Lentinan, a (1-3)-β glucan from shiitake 
mushroom increased the expression of MHC II, CD80/CD86, and Toll-like receptors 
(TLR2/TLR4), and increased production of IL-12 in spleen dendritic cells from malaria-
infected mice (Zhou LD 2009). These findings suggest SM promote Th1 response during 
Plasmodium yoelii infection in mice. 
Surprisingly, hemicellulase-treated Agaricus blazei mushroom activated BMDCs, 
without producing proinflammatory cytokines, such as IL-12, TNF-α, and IL-1β. 
(Kawamura M 2005). In contrast to the above observation, the water-soluble 
proteoglycan isolated from Agaricus blazei caused not only the maturation of murine 




2005). However, in another study extracts from Agaricus blazei augmented NK cell 
activation by increasing IL-12 and IFN-γ production in mouse DCs. (Yuminamochi E 
2007) Recently, the extracts from Agaricus blazei Murill were shown to stimulate 
monocyte-derived dendritic cells and up-regulate pro-inflammatory molecules including 
IL-8, G-CSF, TNF-α, IL-1β, IL-6 and MIP-1β. Although extracts from Agaricus blazei 
Murill increased pro-inflammatory molecules in this in-vitro study, it did not induce the 
synthesis of Th2 cytokines or the Th1 specific cytokine IL-12 (Førland DT 2010).  
Surprisingly, water soluble extracts from Hericium erinaceum, a medicinal mushroom 
activated human DCs, without producing IL-12 (Kim SK 2010). Similarly, Armillariella 
mellea caused maturation of human dendritic cells without induction of cytokine 
production (Kim SK 2008). WBM activated BMDCs and up-regulated IL-12 production 
(Ren Z 2008). Unlike mushrooms, yeast derived β-glucan induced more IL-12 production 
by dendritic cells (Driscoll M 2009)  
In summary, exotic mushroom compounds are capable of inducing DCs maturation of in 
vitro. Almost all exotic mushrooms have been shown to produce IL-12 production, but 
their effects on the Th1/Th2 polarization are variable and appear to be highly compound-
specific. However, information regarding the effect of WBM and PM on DCs maturation 
is limited. Moreover, there is not much information about mushrooms on Th17 
polarization. 
Animal models of intestinal inflammation 
Animal models of intestinal inflammation/inflammatory bowel disease (IBD) served as 




novel treatment strategies (Blumberg RS et al 1999 and Strober W 2002). Currently, 
there are about 20 animal models of intestinal inflammation being employed to 
investigate the roles of environmental factors such as normal bacterial flora, diet and the 
genetic composition and their interactions on the development of intestinal inflammation 
(Blumberg RS et al 1999, Strober W 2002 and Wirtz S & Neurath MF 2000). Although 
these animal models of intestinal inflammation do not mimic the exact nature of human 
disease, still they are vital to answer complex research questions which cannot be carried 
out on humans due to ethical, legal and technical considerations (Strober W 2002 and 
Wirtz S & Neurath MF 2000).  
Animal models of intestinal inflammation are classified into four major categories:          
i) inducible colitis models, ii) spontaneous colitis, iii) adoptive transfer model and          
iv) genetically engineered animal models (e.g., knockout (KO) models and transgenic 
models). In inducible colitis models, chemical agents such as acetic acid (MacPherson 
BR and Pfeiffer CJ 1978), dextran sodium sulfate (DSS) (Okayasu I et al 1990), 
trinitrobenzene sulfonic acid (TNBS) (Morris GP et al 1989 and Neurath MF et al 1995), 
and oxazolone (Boirivant M et al, 1998) are used to induce intestinal inflammation and 
tissue damage.   
These chemically induced intestinal inflammation animal models are commonly used in 
biomedical research due to easy access, low expense, low technical demand and 
reproducible effects within a short period of time (Strober W 2002). In fact, DSS induced 
acute colitis is an invaluable tool to study the role of innate immunity involved in colitis 
(Jurjus AR et al 2004). It is known that oral administration of 3-5% of DSS for 5-7 days 




presence of neutrophils and macrophages within inflamed mucosa (Okayasu I et al 1990). 
Therefore, DSS is a useful model to investigate the role of various leukocytes during 
colitis (Maisoun A et al 2006).  
On the other hand, repeated DSS treatment at the rate of 0.5% to 2% leads to chronic 
colitis characterized by large numbers of activated T cells in the intestinal mucosa (Wirtz 
S 2007). Hence, DSS induced chronic colitis is a valuable tool to study the mechanisms 
linking colitis to colon cancer (Wirtz S 2007). Similarly, rectal administration of TNBS 
dissolved in ethanol promotes a severe intestinal inflammatory response (Morris GP et al 
1989 and Neurath MF et al, 1995). In this model, ethanol is used to increase intestinal 
permeability which allows TNBS to reach the intestinal mucosa and haptenate tissue and 
microbial proteins. Therefore, haptenating TNBS compound-induced colitis is an 
invaluable model to study the T helper cell-dependent mucosal immune responses unlike 
DSS (Jurjus AR et al, 2004 and Wirtz S 2007).  Moreover, TNBS induces Crohn’s 
Disease-like intestinal inflammation whereas DSS induces ulcerative colitis in these 
animal models (Neurath MF et al, 1995 and Maisoun A et al 2006).  However, both 
chemicals can be used to activate the mucosal immune response in GI tract (Blumberg 
RS et al 1999).  
The striking feature of the induced inflammation model is the disruption of the epithelial 
cell barrier by these chemicals (MacPherson BR & Pfeiffer CJ 1978, Okayasu I et al 
1990, Morris GP et al 1989, Neurath MF et al 1995, and Boirivant M et al 1998). 
Disruption in epithelial barrier leads to increased cellular exposure to mucosal microflora. 
This results in mucosal inflammation and non-specific activation of mucosal immune 




chemically-induced intestinal inflammation models are widely used, these animal models 
have some disadvantages. One of the disadvantages is the leakage of these chemicals into 
a proximal portion of the intestine, causing inflammation similar to that seen in the colon. 
Moreover, these chemicals induce severe inflammation and nutrient malabsorptions. 
Therefore, disrupting the mucosal barrier by using electrocautery methods seems be an 
alternative to chemically induced intestinal inflammation (Mourad FH et al, 2010). 
Unlike induced model of colitis, spontaneous colitis develops naturally in a few mouse 
strains such as C3H/HeBir (Sundberg JP et al, 1994) and SAMP1/Yit (Burns RC et al, 
2001) due to genetic mutation. These spontaneous mutant mouse models are useful to 
study the inheritable form of inflammatory bowel disease and the role of genetic 
composition in the development of intestinal inflammation. Interestingly, in adoptive 
transfer model, intestinal inflammation is transferred from immunocompetent mice to 
immunodeficient mice through immune reactive CD4+ T cells (Powrie F et al, 1993). 
These adoptive transfer models are used to study the role of T cells in regulating 
intestinal inflammation and autoimmune diseases. Several gene-knockout mouse strains 
such as IL-2, IL-10 and T cell receptor (TCR) have been developed to define the role of 
the immune system in the development of intestinal inflammation. (Sadlack B et al, 1993, 
Davidson NJ et al, 1996, Mombaerts P 1993, Rudolph U et al, 1995 and Hermiston ML 
& Gordon JI). Unlike induced animal models, these genetically modified mice are 
relatively expensive and technically demanding. Moreover, these mouse strains might 
have developed physiological adaptation/compensatory mechanism to these targeted 





Cytokines and intestinal inflammation 
 
A large number of cytokines including TNF-α, IL-6, IL-12, IL-17, IL-23 and IL-10 are 
known to be up/down-regulated during intestinal inflammation. Among these cytokines, 
TNF-α is a well-studied proinflammatory cytokine during intestinal inflammation (Rogler 
G and Andus T 1998). Macrophages located within lamina propria are the major source 
of TNF-α during intestinal inflammation (Neurath MF et al 1997) and over expression of 
TNF-α is the common feature of any animal model of intestinal inflammation (Rogler G 
and Andus T 1998). Interestingly, TNF-α knockout mice were less susceptible to TNBS 
induced colitis (Neurath MF et al 1997), while the other hand, TNF-α transgenic mice 
were highly susceptible to TNBS induced colitis (Neurath MF et al 1997). TNF-α 
blockade by using specific antibodies or pharmacological agents were shown to reduce 
intestinal inflammation (Murthy S et al 1999).  
 
Dysregulated TNF-α production has been implicated in various inflammatory disorders 
including rheumatoid arthritis, IBD and psoriasis (Chatzantoni K and Mouzaki A 2006). 
It is known that TNF-α promotes inflammatory reactions by recruiting activated 
inflammatory cells to the site of injury or inflammation (Sun WY et al 2010). TNF-α 
activates NF-κB, signaling pathways in promoting inflammation (Escobar GA et al 
2006). IL-6, a B-cell stimulator factor-2 plays an important role in the intestinal 
inflammation (Mudter J and Neurath MF 2007). Increased IL-6 expression is frequently 
reported in IBD and in animal models of intestinal inflammation (Mudter J and Neurath 
MF 2007).  IL-6 blockade helps to reduce the severity of colitis in both experimental and 





IL-12 is mainly produced by activated macrophages which are involved in the Th1 
responses (Tozawa K et al 2003). Up-regulation of IL-12 production has been 
demonstrated in TNBS-induced colitis mouse model (Tozawa K et al 2003). IL-23 plays 
an important role in the inflammatory response against infection, and the expression is 
increased in IBD (Sarra M et al 2010).  IL-23, together with TGFβ and IL-6 stimulate 
naïve CD4+ T cells to differentiate into Th17 cells, which secrete IL-17 (Sarra M et al 
2010). IL-23 and IL-17 cytokines act together to participate in gut immunity and 
intestinal inflammation (Feng T et al 2011).  Interestingly, IL-10 is known to reduce 
intestinal inflammation (Tomoyose M et al 1998, Paul G et al 2011 and Yanaba K et al 
2011). In fact, IL-10 knockout mouse is more susceptible to colitis (Larmonier CB et al 
2011). 
 
Mushrooms and inflammation 
Mushroom extracts obtained from Inonotus xeranticus, Pholiota nameko mushrooms 
showed anti-inflammatory effects on in-vitro and in-vivo models (Lee YG et al 2008 & 
Li H 2008). Isolated mushroom constituents have been shown to have beneficial effects 
on experimental inflammation and cancer. Many of these compounds are large 
polysaccharides or β-(1→6)-branched β-(1→3)-linked glucans. β-glucan is one of the 
active components believed to be responsible for the beneficial effects of mushrooms.  
Prophylactic administration of water soluble β-glucans attenuated lipopolysaccharide 




the Inonotus xeranticus mushrooms inhibited signaling cascade through nuclear factor 
kappa B (Lee YG et al 2008). 
Although mushrooms are known for their high concentration of β-glucan, mushrooms 
also contain polyphenols and ergothioneine (Mau J 2002 & Akanmu D 1991). These 
bioactive compounds act as an antioxidant thereby suppressing chronic inflammation. In 
an in vitro study using human aortic endothelial cells (HAEC), the extracts of WBM 
reduced the IL-1β induced expression of adhesion molecules such as VCAM-1, ICAM-1, 
and E-selectin-1 (Martin KR 2010) 
β-glucan obtained from Agrocybe chaxingu  has been shown to inhibit LPS-induced nitric 
oxide (NO) and cyclooxygenase-2 (COX-2) expression in Raw 264.7 cells, a murine 
macrophage cell line (Lee BR, 2009). Moreover, topical application of this β-glucan 
reduced ear edema which is caused by an inflammatory agent 12-O-tetradecanoylphorbol 
13-acetate (TPA)-TPA-induced ear edema mouse model (Lee BR, 2009). Interestingly, 
oral administration of proteoglycan derived from medicinal mushroom scientifically 
known as Phellinus linteus reduced the severity of collagen-induced arthritis (CIA) by 
suppressing pro-inflammatory cytokines, including IL-12, TNF-α, and IFN-γ (Kim GY 
2003). 
In an in vivo study, ethanolic extract of Phellinus linteus was shown to have anti-
inflammatory effect in croton oil -induced ear edema model and acetic acid-induced 
writhing test mouse model (Kim SH 2004). Similarly, 70% ethanolic extracts of 




carrageenin-induced edema but also anti-angiogenic and antinociceptive activites (Kim 
SH 2004).  
Mushrooms and intestinal inflammation 
Oral administration of water soluble extracts from the edible mushroom “Pleurotus 
pulmonarius” attenuated the 3.5% DSS induced acute colitis in mouse model (Lavi I 
2010). The protective action of “Pleurotus pulmonarius” was due to its inhibitory effect 
on pro-inflammatory molecules including TNF-α, IL-1β and myeloperoxidase.  In 
another study, oral supplementation of Pleurotus ostreatus, an edible mushroom has been 
shown to inhibit tumor growth in DSS induced colorectal cancer mouse model in a dose 
dependent manner (Jedinak A 2010). Moreover, Pleurotus ostreatus supplementation 
suppressed the expression of COX-2 and cyclin D1 in this mouse model. (Jedinak A 
2010).  
Han ES et al (2011) have studied the anti-inflammatory of Cordyceps militaris extract on 
DSS-induced acute colitis model. In this study, Cordyceps militaris, a medicinal 
mushroom elicited anti-inflammatory activity in both DSS-induced colitis mouse models 
and LPS-stimulated RAW264.7 in vitro cell culture. Similarly, water soluble extract of 
Maitake mushroom (Grifola frondosa) has been shown to protect TNBS-induced colitis 
in rat models. (Lee JS 2010). The beneficial effect of Maitake mushroom appears to be 
through suppression of TNF-α.   
Unlike previous studies, whole mushroom powder (2% WBM) supplementation caused 




supplementation protected these mice from DSS induced colonic injury in spite of their 
pro-inflammatory response (Yu et al 2009) 
β Glucans on Immunity and Inflammation 
β Glucans are naturally occurring complex homopolymers of glucose found in integral 
cell wall of plants and fungi.  These polysaccharides have 1, 3- or 1-4 beta linkage with 
with or without β -1, 6-(D)-glucose side chains. β glucans have attracted much attention 
due to their biological response modifying (BRM) action that potentiates and modulates 
the immune response.  
In a recent study conducted by Kim et al, authors used sparan, a 1,3-β-D-glucan isolated 
from a medicinal mushroom called Sparassis crispa for activating dendritic cells. 
Different mouse strains including TLR4⁻/⁻ knock-out mice and TLR4-mutated C3H/HeJ 
were used to collect spleenocytes and bone marrow derived dendritic cells (DCs) (Kim et 
al 2010). Surface markers of dendritic cell maturation such as CD40, CD80, CD86, and 
MHC-I/II molecules were evaluated by flow cytometry whereas cytokines (IL-12, IL-1β, 
TNF-α, and IFN-α/β) secretion were assessed by ELISA method. Addition of sparan 
caused phenotypic and functional maturation of dendritic cells (DCs) derived from 
TLR4-mutated C3H/HeJ mice. On the other hand, sparan did not cause maturation of 
DCs generated from bone marrow cells of tlr4⁻/⁻ knock-out mice. This clearly suggests 
TLR4 receptor is required for sparan action. Moreover, addition of sparan increased 
phosphorylation of ERK, p38, and JNK, and enhanced nuclear translocation of NF-κB 





In another study, authors Agarwal S et al, used curdlan, an isolated β—glucan, to activate 
human dendritic cells. Dendritic cells were isolated from blood obtained from healthy 
volunteers. Cytokines secretion including IL-23, IL-1β, IL-6 and IL-12p70 were 
determined by ELISA. Cytotoxic T lymphocyte assay was performed against target tumor 
cells. In this study, the curdlan-stimulated DCs helped not only to polarize naïve CD4 
cells into Th17 and Th1 cells but also induce differentiation of B cells to secrete IgG and 
IgA (Agarwal S et al 2010). Moreover, curdlan-stimulated DCs enhanced the cytotoxic T 
lymphocyte activity in vitro (Agarwal S et al 2010). These results suggest curdlan as a 
promising agent/ adjuvant to stimulate mucosal and systemic immune response in 
humans. 
Unlike earlier studies,  in this study Volman JJ et al, used dietary form of β--glucan rather 
than isolated β--glucan compounds for activating bone marrow-derived macrophages. 
Moreover, authors used Caco-2 cell line, a human enterocyte cell line in addition to bone 
marrow-derived macrophages from mice. Effects of mushroom extracts on nitric oxide 
production by bone marrow-derived macrophages (BMMs) from mice and on nuclear 
factor-kappaB transactivation in human intestinal Caco-2 cell were evaluated. All 
mushroom extracts containing β--glucan lowered nuclear factor-kappaB transactivation in 
Caco-2 cells. In this study, white button mushroom extract containing β--glucan 
(Agaricus bisporus) stimulated BMM, without activating Caco-2 cells (Volman JJ et al 
2010). These results suggest white button mushroom might be considered as an adjuvant 





Non-alcoholic fatty liver disease (NAFLD) 
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disease ranging from simple 
steatosis, to inflammatory steatohepatitis (NASH) with fibrosis that leads to cirrhosis (de 
Alwis NM and Day CP 2008). As the term “Non-alcoholic” infers the development of 
fatty liver occurs in the absence of excessive alcohol intake. NAFLD is increasingly 
being recognized as “hepatic manifestation of the metabolic syndrome” (Lewis GF et al 
2002). This is due to its intimate relationship with obesity and insulin resistance (Sanyal 
AJ et al 2001). Moreover, NAFLD has been frequently observed in the obese and type 2 
diabetic populations (Vuppalanchi R and Chalasani N 2009).  Due to the prevalence in 
obesity and type 2 diabetes, NAFLD has emerged as the most common cause of liver 
disease in the Western world. Interestingly, NAFLD has also been observed in lean Asian 
population (Kausik Das et al 2010). This suggests that factors other than obesity, 
alteration in glucose metabolism might contribute to the development of NAFLD in this 
population (Kausik Das et al 2010). 
Despite recent advances in elucidating the complex metabolic and inflammatory 
pathways involved in NAFLD, the etio-pathogenesis of NAFLD is not yet fully 
understood (Petta S et al 2009). Although the etiology of NAFLD may vary from 
populations, it is evident that NAFLD is a global public health problem (Everhart JE and 
Bambha KM 2010). Histopathology of liver is the gold standard in diagnosing clinical 
cases of fatty liver (Shifflet A and Wu GY 2009). Moreover, histopathology helps to 
differentiate simple fatty liver disease from NASH (Kleiner DE et al 2005). However, 




(Shifflet A and Wu GY 2009). Hence, developing non-invasive diagnostic tests for 
NAFLD has become imperative (Shifflet A and Wu GY 2009).  
Animal models of NAFLD 
To understand the pathogenesis of NAFLD, numerous cross-sectional studies have been 
conducted (Vernon G et al 2011).  In humans the process of NAFLD from simple fatty 
liver to NASH takes decades which makes it difficult to obtain the quality data and the 
ethical constraints in obtaining human liver tissue limit the human studies. Therefore, 
much attention is being focused on the development of animal models of NAFLD 
recently (Hebbard L and George J 2011).  Moreover, these animal models can be used as 
reductionist approach to evaluate the role of a gene or dietary factor or combination of 
both in the development of NAFLD (Hebbard L and George J 2011).   
Diet induced NAFLD animal models are widely used to study the pathogenesis of 
NAFLD. High fat, fructose, cholesterol diets and low methionine & choline diets are 
some examples of diet-induced NAFLD animal models (Zou Y et al 2006, Spruss A & 
Bergheim I 2009, Matsuzawa N et al 2007 and Rinella ME et al 2008). However, none of 
these animal models exhibit the complete range of histopathological, metabolic and 
biochemical changes associated with progression of NAFLD in humans (Hebbard L and 
George J 2011). This may be due to species difference in the metabolic response to fat 
overload. Genetically altered mice such as adiponectin null, TLR9 null in combination 
with high fat diet have also used to study the NAFLD (Asano T et al 2009 and Miura K et 





Cytokines and NAFLD 
Proinflammatory cytokines such as TNF-α and IL-6 have been implicated in the 
development of obesity-associated insulin resistance and fatty liver (McClain CJ et al 
1999).  In animal models of obesity, increase in TNF-α were found not only in adipose 
tissue but also in liver suggesting the possible role of TNF-α in diet induced fatty liver 
(Xu H et al 2002 and Feldstein AE et al 2004). Further, in vivo administration of TNF-α 
impairs insulin action, (Peraldi P et al 1996 and Hotamisligil GS et al 1996) whereas 
TNF-α blockade improved insulin sensitivity in animal models of obesity (Uysal KT et al 
1997). Plasma TNF-α levels and TNF-α polymorphisms are positively correlated with the 
degree of insulin resistance and NAFLD in humans. (Wellen KE et al 2005). It appears 
that TNF-α-induce insulin resistance and fatty liver through Jun N-terminal kinase (JNK) 
pathway (Shoelson SE et al 2006). Accumulating evidence based on experimental and 
clinical studies strongly supports the role of TNF-α in the inflammation, insulin 
signaling, and fatty liver. 
Unlike TNF-α, IL-6 plays dual role in inflammation and NAFLD. Immune cells, 
endothelial cells, and adipocytes are the major sources of plasma IL-6 (Mohamed-Ali V 
1997). It has also been reported that hepatocytes are capable of producing IL-6 (Jung BD 
et al 2000). IL-6 is shown to improve hepatic regeneration and repair during acute 
administration of IL-6 into hepatocytes (Jin X et al 2006). On the other hand, chronic 
exposure to excess IL-6 sensitizes the hepatocytes to apoptosis (Jin X et al 2006). 
Convincing in vitro and in vivo studies have been postulated that IL-6 as a contributing 
factor in the hepatic manifestation of the metabolic syndrome (Klover PJ et al 2002). 




experimental and clinical NAFLD (Polyzos SA et al 2009). In clinical NAFLD, increased 
IL-6 expression in hepatocytes and Kupffer cells is positively correlated with NAFLD 
progression (Dogru T et al 2008). In summary, the the elevated plasma IL-6 might be the 
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Background: IL-23, a novel cytokine produced primarily by dendritic cells, is involved 
in host defense against gut pathogens such as Vibrio cholerae and E. coli and promotes 
gut immune function through the IL-23/IL-17 axis. Although certain exotic mushrooms 
have long been used in Asia for treatment and/or prevention of infection due to their 
immuno-stimulatory properties, there is a paucity of data on the effect of white button 
(WBM) and portabello (PM) mushrooms on IL-23 and gut immunity.  
Hypothesis:  Since the IL-23/IL-17 axis is involved in the production of defensins in gut 
mucosa, we hypothesized that edible mushroom supplementation may enhance gut 
immunity by up-regulating IL-23 production both in vivo and in vitro. 
Methods: To test our hypothesis, we conducted in vivo and in vitro studies using 
C57BL/6 mice and a murine macrophage cell line 
Two-month-old female C57BL/6 mice were fed either AIN93-control diet or the AIN93 
diet supplemented with 5% WBM, PM or shiitake mushrooms (SM) (n=16/group) for six 
weeks. To assess in vivo cytokine secretion, 8 mice in each group received 3% dextran 
sodium sulfate (DSS) in their drinking water during the last 5 days of the 6-week feeding 
period. Upon euthanasia, blood was collected, centrifuged, and plasma was aliquoted for 
cytokine studies. The length of colon tissue was assessed to determine the shortening of 
colon during inflammation. The severity of colon inflammation and number of lymphoid 
follicles were assessed by histopathology. Sections of colon were also homogenized, 
centrifuged, and supernatants were collected and processed for subsequent determination 





Single cell suspensions were prepared from spleens of DSS treated and untreated mice 
fed mushroom-fortified and unfortified diets. To assess the effect of mushroom and DSS 
treatments on cytokine secretion by non-gut immune cells, 2 x106 spleen cells/ml were 
incubated with Concavalin A, Lipopolysaccharide (LPS) (2.5 µg/ ml) or culture medium 
(baseline) for 72 h. Cells were then centrifuged and the supernatants were collected and 
stored for cytokine assays.  
To further assess the mechanisms by which mushrooms alter cytokine secretion the 
murine macrophage cell line, J.744.1 cells were incubated with curdlan, a dectin-1 
agonist (100 µg/ml), LPS (100 ng/ml), WBM, PM, and SM (100 µg/ml, each) alone or in 
combination with curdlan or 1 mg/ml laminarin (a dectin-1 antagonist) for 3 and 6 days 
for cytokine assay. Cytokines IL-23, IL-6, TNF-α, and myeloperoxidase (MPO), an 
indicator of neutrophil infiltration were measured in plasma, colon homogenate and 
spleen cell supernatant by using ELISA kits.  
Results: In DSS-untreated mice, mushroom-supplemented diets increased plasma IL-23 
(2 to 15-fold); but decreased IL-6 (45%-98%; p<0.05). In DSS-treated mice, mushroom-
supplemented diets increased IL-6 (1.4 - 3.7 fold) and IL-23 (10-50 fold) (p <0.05). DSS 
alone increased plasma IL-6 and IL-23 by ≥ 4 fold (p<0.05), with the highest increase 
occurring in mice fed WM-diet. Similarly, colonic IL-6 and MPO expression or 
productions were elevated after DSS administration. Mushroom-supplementation did not 
elicit an increase in ex vivo IL-6 secretion by activated spleen cells from these DSS 




After DSS treatment, all the mice irrespective of their dietary treatments developed 
inflammation and infiltration of neutrophils and mononuclear cells which are evidenced 
by colon histopathology and high inflammation scores. Among dietary treatments, WBM 
had massive infiltration of neutrophils and mononuclear cells with high mean 
inflammation score (3.6 WBM vs 1.8 Control) followed by PM, SM and control. 
Similarly, the WBM treated mice had elevated colonic MPO (64.7 ng/mg of protein in 
WBM versus 51.2 ng/mg of protein in Control) and decreased colon length. After DSS 
treatment, only mice fed the control diet showed increased number of lymphoid follicles 
compared to those fed mushroom fortified diets. PM extracts, but not other mushrooms, 
up-regulated IL-23 secretion by J.744.1 cells on the day 3 of incubation. All mushroom 
extracts potentiated curdlan-induced IL-23 secretion.  Further, WBM, PM induced IL-23 
secretion was completely blocked by the dectin-1 antagonist, laminarin.  
Conclusion: Data suggest that mushroom consumption may increase gut immunity and 
provide resistance against certain pathogens through the up-regulation of IL-23. These 













The gastrointestinal (GI) tract is vital organ in nutrient absorption and host defense 
against pathogens (Nagler-Anderson C 2001). As much as 90% of pathogens enter into 
the body through the mucosa (Nagler-Anderson C 2001). The GI immune system is 
composed of mesenteric lymph nodes, Peyer’s patches and lamina propria associated 
lymphocytes (Mowat AM 2003). Unlike other immune systems in the body, the GI 
immune system has the constant challenge of responding to pathogens without 
responding to food antigens or the commensal microflora (Mowat AM 2003). Cytokines 
produced by the intestinal dendritic cells play a major role in orchestrating the innate and 
adaptive arms of the immune system (Perdigon G et al 2002). Although several cytokines 
are involved in mucosal defense against pathogens, IL-23 is crucial in the fight against 
bacterial and fungal pathogens encountered in GI mucosa (Doisne JM et al 2010& 
Brereton CF et al 2011). 
IL-23 is a cytokine produced primarily by dendritic cells and to some extent by paneth 
cells (Doisne JM et al 2010 & Ciccia F et al 2009). In conjunction with IL-6 and TGF-β1, 
IL-23 stimulates naive CD4+ T cells to differentiate into a novel subset of cells called 
Th17 cells (Maloy KJ & Kullberg MC 2008). These Th17 cells secrete IL-17, a cytokine 
which is involved in the primary and first line of defense against pathogens by recruiting 




23/IL-17 axis plays a major role in local intestinal inflammation and production of 
defensin in gut mucosa (Uhlig HH et al 2006).  
Therefore, the IL-23/IL-17 axis is involved both directly and indirectly in combatting 
most GI pathogens, including Vibrio cholera, E. coli and Salmonella (Doisne JM et al 
2010). IL-23 also promotes immunological memory by stimulating CD4+ T memory cells 
proliferation. Hence, increasing mucosal IL-23 production might improve mucosal 
immunity/immunological memory (Agrawal S et al 2010).  
Although most GI tract pathogens have been eradicated, food borne diseases such as 
Salmonellosis, Campylobacteriosis, E. coli infections, listeriosis, and Cholera are still 
major public health problems (Meyer C et al 2010&de la Cabada Bauche J, Dupont HL 
2011). Several antibiotics have been developed to treat GI tract infections, including the 
above mentioned food borne diseases; however, a search for alternatives to these 
antibiotics is necessary due to the emergence of antibiotic resistant bacteria (DuPont HL 
2005). Moreover, these antibiotics can destroy or alter the commensal bacteria present in 
the GI tract which leads to the condition called intestinal dysbiosis. It is now believed that 
dysbiosis is a contributing factor to many chronic and autoimmune diseases such as 
irritable bowel syndrome, inflammatory bowel disease, rheumatoid arthritis, and 
ankylosing spondylitis (Hawrelak JA,Myers SP 2004).  
One alternative to antibiotic therapy is to increase the production of endogenous 
antimicrobial peptides such as defensins by using natural compounds or functional foods 
(Cunliffe RN 2003 &Wehkamp J et al 2005). In this regard, several mushroom varieties 




system (Brochers AT et al 2008). Although medicinal mushrooms such as Shiitake have 
long been used in Asia for treatment and/or prevention of infection due to their immuno-
stimulatory properties, there is a paucity of data on the effect of white button (WM) and 
portabello (PM) mushrooms on IL-23 and gut immunity in general (Brochers AT et al 
2008). 
Previously, we found that the extracts from edible mushroom enhance α-defensin 
production in the human promyelocytic cell line HL60 (Solo Kuvibidila& Kiranmayi 
Korlagunta). Since the IL-23/IL-17 axis is involved in the production of defensins in gut 
mucosa, we hypothesized that: (a) the edible mushroom supplementation may enhance 
gut immunity/inflammation by up-regulating IL-23 production in the gastrointestinal tract 
and to a less extent in peripheral lymphoid organs such as spleen; and (b) mushrooms up-
regulate IL-23 through the dectin-1 pathway.   
Experimental design and methods:  
Two types of studies were conducted: a mouse model study and a murine macrophage 
cell line study. 
i. Animal study:  
Animal feeding: The protocol was approved by IACUC of Oklahoma State University 
and all the experimental procedures were strictly followed as per the approved protocol. 
Two-month-old female C57BL/6 mice (n=64) were purchased from Jackson Laboratories 
and acclimatized to our laboratory  for a week. After this acclimation, mice were fed 
either AIN93-control diet or the same diet supplemented with 5% WM, PM or SM 




each group received 3% dextran sodium sulfate (DSS) in drinking water during the last 5 
days of the 6-week feeding period. All mice were sacrificed immediately after DSS 
treatment. 
Tissue collection and Histopathology: 
Upon euthanasia, blood was collected for plasma cytokine analysis and spleen was 
collected from each mouse in a sterile manner and weighed. Thymus was also removed 
and weighed for each mouse. In order to measure the length of colon, the entire portion of 
large intestine from cecum to anus was removed and the length was evaluated as 
previously described (Okayasu I et al 1990). After measuring the colon length, a small 
piece from the distal part of the colon from each mouse was collected in a vial containing 
10% buffered formalin for histopathological analysis. The remaining portion of colon 
was frozen for colon homogenate. The severity of colon inflammation and the presence 
of number of lymphoid follicles were evaluated in a blinded manner by the study 
pathologist. The inflammation score was based on the extent of infiltration of 
inflammatory cells, mucosal injury, loss of crypts and surface epithelium on a scale from 
0 to 4 (0–4: none, basal 1/3 damaged, basal 2/3 damaged, only surface epithelium intact, 
entire crypt and epithelium lost) (Vowinkel T  et al 2004). 
Colon homogenate for cytokines and MPO assay: 
Colons were homogenized in 1 ml ice-cold lysis buffer (Radio-immunoprecipitation 
assay, RIPA buffer) by using a tissue homogenizer (VWR PowerMax Advanced 
Homogenizing System 200 987556). The buffer contained 1% protease inhibitor cocktail 




R) for 15 min at 1400 × g, 4oC and the supernatant transferred to Eppendorf tubes for 
cytokines and MPO assay (In-Ah Lee et al 2010). 
In vitro cytokine secretion by spleen cells: 
Spleen single cell suspensions from various mice were prepared by filtration through a 
cell strainer (Becton Dickinson) as previously described (Kuvibidila SR et al 1998). Cells 
were centrifuged at 290 x g, and red blood cells were lysed by ice cold deionized water 
followed by centrifugation.Cell membrane and viability were determined by trypan blue 
exclusion test.  Spleen cells (2 x 106 cell/ml, 24-well plates) were cultured in complete 
RPMI 1640 medium supplemented with 100 ml/L FBS, mmol/L HEPES, 2 mmol/L 
glutamine, 100 U/L penicillin and 100 mg/L streptomycin (Invitrogen). To assess the ex 
vivo cytokine secretion cultured-splenocytes were incubated with LPS, (2.5 μg/ml), Con 
A (2.5 μg/ml) or culture medium only for 72 h. At the end of incubation period, plates 
were centrifuged (Eppendorf Centrifuge 5810) at 290 x g for 10 min at 4oC. Supernatants 
were collected and aliquots of 500 µl were immediately frozen at -80ºC until used for 
cytokine assays by enzyme-linked immunosorbent assay (ELISA).  
ii. Murine macrophage study using J.744.1 cells: 
In order to assess the mechanisms by which mushrooms alter IL-23 secretion and/or other 
cytokines, we used a mouse cell line J.744.1 (ATTC, Manassas, VA 20108, USA). Under 
certain conditions, these cells can be induced to differentiate into dendritic cells (Jiang X 
et al 2008).  J.744.1 cells were cultured in DMEM supplemented with 100 ml/L FBS, 2 
mmol/L glutamine, 100 U/L penicillin and 100 mg/L streptomycin (Invitrogen), 1.5 g/L 




were cultured in a humidified atmosphere of 95% air and 5% CO2. For cytokine 
secretion, 5 × 105 cells were seeded into a six-well tissue culture plate (2 ml/well) and 
were incubated with either curdlan (100 µg/ml), LPS (100 ng/ml), WBM (100 µg/ml), 
PM (100 µg/ml), SM (100 µg/ml) alone or in combination with curdlan (Sigma: C7821; 
Curdlan from Alcaligenes faecalis), a known dectin-1 agonist (100 µg/ml) or with 
laminarin (Sigma: L9634; Laminarin from Laminaria digitata), a dectin-1 antagonist (1 
mg/ml) for 3 days and 6 days. The supernatant from this cell culture were collected and 
stored immediately in -80o C until used for cytokine analysis. 
Cytokine detection: 
Commercially available ELISA kits (R&D Systems, Minneapolis, MN) were used to 
determine the levels of IL-23, IL-6, TNF-α and MPO in serum, colonic homogenates and 
the supernatants from spleen cells and J.744.1 cell cultures.  
Statistical analysis: 
Statistical analyses were performed using SPSS or Microstatistical program. Descriptive 
statistics were evaluated. Data were expressed mean ± SEM. Post-hoc multiple 
comparisons were made when the F value in ANOVA reached significance. P values of ≤ 
0.05 were considered as significant.  
Results:  
Effect of dietary treatment on body weight & thymus weight  
After DSS administration, all mice showed significant loss in body weight and thymus 




of the dietary interventions prevented thymic atrophy associated with DSS treatment. (Fig 
1B) 
Effect of mushroom supplementation on plasma IL-23 with or without DSS 
challenge 
In DSS-untreated mice, PM-supplemented diet significantly increased plasma IL-23 (p 
<0.05; Figure 2A) compared to the control, WBM and SM. In DSS-treated mice, 
however, all three types of mushrooms significantly (p <0.05) increased plasma IL-23 
compared to control group. Among dietary treatment WBM had the highest plasma IL-23 
followed by the PM and SM groups (p < 0.05; Figure 2B).  
Effect of mushroom supplementation and with or without DSS treatment on plasma 
IL-6 levels 
DSS alone increased plasma IL-6 by ≥ 3.91 fold (p<0.05), with the highest increase 
occurring in mice fed WM-diet (Figure 3B). Similarly PM supplementation also 
significantly (p <0.05) increased the plasma IL-6 levels after DSS challenge. However 
SM did not increase plasma IL-6 levels. 
Effect of mushroom supplementation on IL-6 secretion by spleen cells 
LPS-activated spleenocytes obtained from mice fed mushroom supplemented diets and 
treated with DSS did not show any increase in IL-6 secretion (Figure 4A). Moreover, 
none of the dietary treatments produced alteration in IL-6 that reached the level of 
statistical significance. 




Regardless of dietary treatment, DSS administration significantly increased MPO levels 
in the colon homogenates relative to untreated mice (Figure 5A, p <0.05). While WBM 
supplementation increased colon IL-6 levels, unlike PM, SM decreased them (Figure 4B).   
Effect of mushroom supplementation on colon length 
There was a significant reduction in colon length following DSS treatment in all mice 
group (Figure 5B, p <0.05). Mice fed WBM-fortified diet had 35% reduction in colon 
length as compared to those fed the control diet that showed only 25% reduction in colon 
length. SM and PM had 28% and 27% reduction in colon length respectively. 
Effect of mushroom treatment on colon histology 
After DSS treatment, all mice regardless of their dietary treatments, developed 
inflammation and infiltration of neutrophils and mononuclear cells which are evidenced 
by colon histopathology and high mean inflammation scores. Among dietary treatments, 
WBM had massive infiltration of neutrophils and mononuclear cells with high mean 
inflammation score (Figure 6 (histology) & Figure 7 (inflammation score)) followed by 
PM, and control (Figure 6 & Figure 7). After DSS treatment, only mice fed the control 
diet showed hyperplasia of lymphoid follicles (Figure 6 & Figure 7) compared to those 
fed mushroom-supplemented diets.  
Effect of mushroom extracts on in vitro IL-23 secretion by the murine J.744.1 
After three days of incubation, only PM extracts significantly induced IL-23 secretion by 
J.744.1 cells (Figure 8). IL-23 was undetectable in all other cultures. PM induced IL-23 




of incubation, IL-23 was detectable in all cultures including control, WBM, PM, 
WBM+curdlan, PM+curdlan, SM+curdlan. Further, WBM- and PM- induced IL-23 
secretion was completely blocked by the dectin 1 antagonist, laminarin. In addition, all 
mushrooms augmented the curdlan induced IL-23 secretion. Interestingly as observed 
with the 3 day-cultures, SM did not cause any upregulation of IL-23 production, but 
dectin-1 blockade lead to production of IL-23.  
Discussion: 
In this study we used 3% DSS oral administration to investigate the effect of edible 
mushrooms on gut immunity with respect to innate immunity and acute inflammation. 
The DSS induced acute colitis model is the accepted model to study innate immunity, 
acute inflammation and neutrophilic function (Okayasu I et al 1990 &Wirtz S et al 1990). 
Interestingly, 5% mushroom dietary supplementation significantly increased the plasma 
IL-23 production in mice challenged with 3% DSS and PM up-regulated the IL-23 
production in mice without DSS challenge. Although all mushroom supplementation 
caused significant increases in IL-23 secretion in DSS treated mice, there was a 
difference in IL-23 response among mushroom diets. This suggests that there may be 
differences in immuno stimulatory action of certain varieties of mushrooms on gut 
immunity. 
Since macrophage/dendritic cells are the major source of IL-23 production, we used 
J.744.1, a mouse monocyte/macrophage cell line to further probe the mechanism through 
which mushroom extracts up-regulate IL-23 production. In our in vitro study, the addition 




up-regulates IL-23 secretion on the 3rd day of treatment unlike other mushrooms. This 
supports our in-vivo observation regarding PM on IL-23 production in normal mice. 
All mushroom extracts potentiated curdlan, a Dectin-1 agonist increase in IL-23 secretion 
suggesting the Dectin-1 mediated mechanism.  Further, WBM, PM induced IL-23 
secretion was completely blocked by laminarin, a Dectin-1 antagonist. These findings 
suggest Dectin-1 pathway is involved in the WBM and PM induced IL-23 production. 
Surprisingly SM alone was not associated with any up-regulation of IL-23 production. In 
fact, Dectin-1 blockade lead to the production of IL-23 suggesting Dectin-1 independent 
mechanism that has yet to be investigated. 
Therefore the observed difference in the IL-23 secretion of mice by various mushroom 
supplementations might be due to the difference in their mechanism of action. Our in 
vitro and in vivo findings suggest that edible mushrooms might activate the macrophages 
and dendrtic cells present in the GI immune system. Mushrooms are the rich source of 
beta glucan, which is the natural ligand for the Dectin-1 receptor present in the 
macrophages and dendrtic cells (Brown GD et al 2002 & Taylor PR et al 2002). In a 
recent study, curdlan, an isolated β glucan and dectin1 agonist showed an increased 
production of IL-23, IL-6, and IL-1 β in dendritic cells isolated from healthy humans 
(Agrawal S et al 2010) Moreover, the curdlan-stimulated DC helped to differentiate naïve 
CD4 cells into Th17 (Agrawal S et al 2010).  
In our study, mushroom dietary supplementation also increased plasma IL-6 production. 
IL-23 in conjunction with IL-6, IL-1 β and TGF-β1, have been shown to stimulate naïve 




IL-17 (Dong C 2008,Manel N et al 2008& Cunin P et al 2011).  This IL-17 cytokine is 
involved in the recruitment of neutrophils, the first line of body defense against bacterial 
pathogens to the site of inflammation (McAleer JP, Kolls JK 2011).  
After DSS treatment, all mice, regardless of their dietary treatments developed 
inflammation and infiltration of neutrophils and mononuclear cells, which is evidenced 
by colon histopathology and high inflammation scores. Among dietary treatments, WBM 
had massive infiltration of neutrophils and mononuclear cells with a high mean 
inflammation score, followed by PM, SM, and control. In addition, the WBM treated 
mice had elevated colonic MPO level, an indication of an enhanced neutrophilic 
response. These results suggest edible mushroom dietary supplementation might shift 
immune response toward a Th17 paradigm through IL-23/IL-17 axis.  
Interestingly, mice fed the control diet showed hyperplasia of lymphoid follicles after 
DSS treatment. However, mushroom supplemented groups showed massive neutrophillic 
infiltration. Lymphoid hyperplasia is frequently found in the histopathology of colonic 
tumors (Masaru Kojima et al 2009). These colonic histological findings suggest that 
mushroom supplementation promotes acute inflammatory response rather than chronic 
inflammatory response, which may lead to malignancy (Masaru Kojima et al 2009).  
Eventhough DSS treated mice lost significant body weight and thymus weight, none of 
the dietary intervention influenced the body weight and thymus weight. This may be due 
to short duration of mushroom dietary treatment as we sacrificed the mice immediately 




In summary, mice fed with mushroom diets for six weeks showed an increase in the 
plasma IL-23, IL-6, colon MPO, colon IL-6, and inflammation score when they were 
challenged with 3% DSS. Although all mushroom up-regulated IL-23, PM up-regulated 
IL-23 secretion on the 3rd day of in vitro treatment and mice without DSS challenge 
unlike other mushrooms. All mushroom extracts potentiated curdlan induced IL-23 
secretion and mushroom induced IL-23 secretion was completely blocked by laminarin. 
These findings clearly suggest Dectin-1 is the major pathway in WBM and PM induced 
IL-23 production. Difference in mushrooms action on IL-23 could partly be explained by 
their mechanism of action on Dectin-1 pathway. To the best of our knowledge, this is the 
first report documenting the possible health benefits of WBM and PM, through up-
regulation of innate immunity/ inflammation through IL-23 pathway.  
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Shiitake is a medicinal mushroom that has long been used in Asia for treatment and/or 
prevention of chronic diseases and hypercholesterolemia in humans. Previously, we 
observed supplementation of the AIN76 diet with 5% lyophilized shiitake elevated 
plasma IL-6 levels by two-fold in DBA arthritis mice. Considering that high plasma IL-6 
has been implicated in fatty liver disease pathogenesis, we hypothesized that 
consumption of a shiitake supplemented diet would lead to transient hepatic steatosis. 
Two studies were conducted. In study 1, eight-week old C57BL/6 female mice were 
randomly assigned to the following groups for 6 weeks: the AIN-93 diet; 5% shiitake 
(SM), and 5% white button mushroom (WBM) supplemented diets (12 mice/group). In 
Study 2, mice were fed either the control or SM (20/group). After 6 weeks, 13 mice fed 
SM diet were given the AIN93 diet for 8 or 15 days. Unlike mice fed the AIN93 and 
WBM diets, mice fed the SM diet developed fatty liver (mean histopathology score 4.5 vs 
<1 in the other groups; p <0.001) without fibrosis and inflammation after 6 weeks of 
supplementation. Fat droplets were detected only in the liver and not other organs. SM 
moderately reduced liver glycogen content. Fifteen days post withdrawal of SM 
completely normalized liver histology. Unlike our previous studies, SM supplementation 
did not increase plasma IL-6 in C57BL/6 mice suggesting a strain difference. Plasma 
triglycerides were 42% higher in mice fed SM diet for 6 weeks and switched to control 
diet for 8 days (p <0.05). Data suggest that SM induces simple reversible hepatic 
steatosis. This is the first time that SM are shown to increase liver fat content and the 






The shiitake mushroom (SM) is an edible medicinal mushroom, scientifically known as 
Lentinula edodes that native to China and cultivated in East Asia (Raymond Chang 
1996). SM was considered a royal food in ancient times due to its medicinal value, 
delicacy and scarcity.  Although SM had been cultivated mainly by traditional methods in 
East Asian countries including Japan, China and Korea before 1982, the advancement of 
mushroom production and biotechnology led to large scale commercial cultivation of SM 
worldwide (Chang & Miles 2004). Presently, SM is the second most cultivated edible 
mushroom comprising about 25% of the worldwide production followed by the white 
button mushroom (WBM) (Jiang T et al 2010).  In the United States, the SM production 
has exceeded 9 million pounds per year during 2009 (National Agricultural Statistics 
Service 2009).  
Because of their widespread availability and significant reduction in price, the 
consumption of SM has increased in recent years. Both fresh and dried forms of SM have 
been used in many East Asian cuisines including vegetarian “miso soup” of Japan and 
has been slowly incorporated into western cuisine in recent years (Chang & Miles 2004). 
Although both forms of SM are used for culinary purposes, some people prefer the dried 
form of SM due to its flavor and vitamin D content (Chang & Miles 2004). Hence, SM is 
often sold as a dried powder for commercial use.  
In a few uncontrolled clinical studies, dried powder of SM has been used in 
complementary and alternative medicine (CAM) therapy to treat hypercholesterolemia 




1996& Bisen PS et al 2010). Interestingly, we recently observed that fortification of the 
AIN76 diet with 5% lyophilized SM was associated with a two-fold significant increase 
(p ≤ 0.05) in plasma interleukin-6 (IL-6) in DBA mice with collagen-induced arthritis 
(Chandra L et al 2011). Activated leukocytes, endothelial cells, and adipocytes are the 
primary sources of circulating IL-6(Pradhan AD et al & Fasshauer M 2003), which 
usually elevated patients with fatty liver disease (McClain CJ et al 1999). Peripheral 
blood monocytes from these patients also secrete higher levels of IL-6 in vitro (McClain 
CJ et al 1999). Thus IL-6 is has been implicated in the pathogenesis of fatty liver disease 
(McClain CJ et al 1999), a review of  the literature revealed very limited information 
available regarding the association between consumption of edible mushrooms and risk 
of non-alcoholic fatty liver disease (NAFLD).  
NAFLD is a disorder of lipid metabolism characterized histologically by hepatic steatosis 
in the absence of excessive alcohol consumption (James E et al 2010). NAFLD has 
drawn much attention among gastroenterologists, endocrinologists, cardiologists, 
physicians and surgeons due to its intimate association with insulin resistance, metabolic 
syndrome, cirrhosis and end stage liver failure (James E et al 2010). Moreover, the 
prevalence and health burden associated with NAFLD has increased globally in recent 
years (James E et al 2010). Although obesity was found to be the major contributing 
factor in the development of NAFLD in Western populations, the prevalence of NAFLD 
also occurs in people with relatively low BMI and waist circumference in East Asian 
countries suggesting other possible factors might be involved in the development of 




Surprisingly, the prevalence of NAFLD in adult Japanese population with normal BMI 
was 29% even though the exact NAFLD prevalence among the general population 
remains unknown (Jimba S et al 2005). Among East Asian countries, the prevalence of 
NAFLD in the population with normal BMI remains high in Japan, the largest consumer 
of shiitake mushroom in the world (James E et al 2010). Based on our observation of 
increased IL-6 plasma levels in mice fed SM-fortified diet, and the high prevalence of 
NAFLD among Japanese, we hypothesized that SM may contribute to the development 
of fatty liver. We used an animal model to investigate the effect of supplementation of the 
AIN93 diet with dry-lyophilized SM powder on fatty liver prevalence in C57BL/6 mice. 
 
Materials and Methods  
Chemicals & Reagents: WBM and SM were a generous gift from JM Mushrooms in 
Miami (OK). An endotoxin assay kit was purchased from GenScript (Piscataway, NJ) 
and AIN93 diet from Teklad (Indianapolis, IN). Triglyceride assay kits were purchased 
from BioVision Research Products, (Mountain View, CA). 
Methods: All the procedures were approved by the IACUC of Oklahoma State University 
(OSU, Stillwater).  Two studies were performed. In the first study, 8-week old female 
C57BL/6 mice (n = 36; body weight 15-18 g) were purchased from Jackson Laboratories 
(Bar Harbor, ME). Upon arrival, they were housed at the OSU laboratory animal research 
facility, 5 mice per cage, and were acclimated to our laboratory while being fed the 
AIN93 for 7 days. At the end of the adjustment period, mice were randomly assigned to 




lyophilized white button mushrooms (WBM), or shiitake mushrooms (SM). The 
nutritional composition of the three different diets is summarized Table-1. All diets were 
formulated to be isocaloric and normal fat diets. 
In the second experiment, 40 eight-week old C57BL/6 female mice were randomly 
assigned into two dietary treatment groups, the AIN93 (control group) and SM group. 
After 6 weeks of feeding, mice that received SM were divided in three sub-groups: SM-I 
continued to receive the SM supplemented diet; SM-II, received the control diet for 8 
days; and SM-III, received the control diet for 15 days. During the feeding protocols, all 
mice had free access to their diets and deionized water, and they were housed under 
standard 12 h light to dark cycle conditions. 
Histopathological analysis: At the time of euthanasia, mice were subjected to CO2 
inhalation for about 60 sec. After they were weighed, the liver, heart and kidneys were 
collected and fixed with 10% buffered formalin. Tissues were embedded in paraffin, and 
5 mm sections were cut and stained with hematoxylin and eosin, periodic acid-Schiff, or 
Masson's trichrome according to standard techniques.  Histopathological changes were 
scored in a blinded manner by using a modified method adopted from Kleiner DE et al 
(Kleiner DE et al 2005). 
Measurement of plasma triglycerides, IL-6, endotoxins and aflatoxins: Plasma IL-6 
was measured by using ELISA kit (R&D Systems, Minneapolis, MN). Triglycerides and 
endotoxins were assayed by colorimetric methods and the methods provided with the kits 
( ) following the manufacturers guidelines or procedure. Samples were sent to Oklahoma 




Statistical analysis: Descriptive statistics (mean ± SEM), analysis of variance (ANOVA) 
and/or Student’s t test, were performed by Microstatistical Program (Microsoft Inc, 
Indianapolis, IN). The level of significance was set at p ≤ 0.05. 
Results  
Effect of mushrooms on food intake, body weights, and organ weights. All three diets 
are isocaloric with similar macronutrient (fat, carbohydrates, proteins) and micronutrients 
except for the 50 g of sucrose that were substituted by lyophilized mushrooms per kg diet 
(Table 1). Table 2 describes the effect of different dietary treatments on food intake and 
body weight and vital organs, including the liver. Under the experimental conditions, 
supplementation of the AIN93 diet with 5% lyophilized SM and WBM did not 
significantly affect the mean food intake or the mean body weights. Moreover, mushroom 
supplementation did not affect absolute or relative mean weights of the liver, kidneys, or 
heart.  
Effect of different dietary treatment on organ histology and histochemistry. Compared 
to mice fed the control (AIN93) diet (Fig 1A), all mice fed SM-fortified diet exhibited 
signs of hepatic steatosis (Fig 1C and Fig 2).  In contrast to SM supplementation, WBM 
supplementation did not induce fat droplets, and in fact showed normal liver histology 
and fatty liver score (Fig 1B and Fig 2). While SM reduced liver glycogen content as 
evidenced by PAS reaction, WBM had no effect on PAS reaction (Fig 1D-F). However 
neither SM nor WBM induced fibrosis and/or excessive inflammation as assessed by 
Trichrome staining (Fig 1G-I). Furthermore, SM supplemented diet did not induce 




accumulations are specific to the liver (Figure 3 D-I). We performed our second study to 
see whether the SM induced hepatic steatosis are reversible or not. Interestingly, as little 
as 8 days of withdrawal of SM supplemented diet were sufficient to reverse and 
normalize liver fat content (Fig 3 B & C). By 15 days of feeding the control diet, liver 
structure was not different from that of mice that received the control diet throughout the 
study period (Fig 3C).  
Effect of SM on plasma triglycerides and IL-6. Contrary to what we expected, mice fed 
SM supplemented diet for 6 weeks, thereafter given the control diet for 8 days showed 
elevated serum triglycerides levels compared to those fed the control (Figure 4). WBM 
had no effect on serum triglyceride levels. Moreover, SM did not elevate plasma IL-6 
levels in these mice as compared to control and WBM diets (data not shown) 
Discussion 
In our first experiment, all mice supplemented with SM alone developed simple hepatic 
steatosis without showing any inflammatory or fibrotic changes in the liver. Moreover, 
SM group mice were fed isocaloric and normal fat diet, but not with high fat or fructose 
diet during SM supplementation. Therefore, the results of the present study suggest that 
SM can induce moderate hepatic steatosis even within the content of an otherwise 
adequate diet. However, SM- induced fatty changes in liver histology were normalized 
within two weeks of SM withdrawal from the diet as observed in the second experiment. 
This cross over design of our second experiment confirmed that dried powder of SM in 
the diet contributed, at least in part; to the development of fatty liver observed in SM 




on the mild-to-moderate reduction of liver glycogen content, it appears that SM induced 
the conversion of dietary carbohydrates to fat rather than glycogen, but this was not the 
case with WBM. This possible induction of fat synthesis in the liver will be the focus of 
our future studies.  
It has been previously shown that both endotoxin and aflatoxin can induce fatty liver 
(Harte AL et al 2010& Newman SJ 2007). To rule out the possibility that increased 
hepatic steatosis was due to low level toxins in the mushrooms, we analyzed the dried 
mushroom powder and diet for the presence of these compounds. However, the levels 
were barely detectable suggesting that the increased fat content was due to another 
component in the SM. Moreover, none of the mice from SM showed toxicological 
changes in the liver, kidneys or heart.  
SM-induced fatty changes were confined to the liver, sparing heart and kidneys 
suggesting liver is the target for SM. One possible or likely explanation for lack of effect 
of SM is that neither the heart, nor the kidneys are major sites for glycogen storage or 
fatty acid biosynthesis. Unlike other hepatotoxic agents such as aflatoxin and endotoxin, 
SM did not appear to induce inflammation, zonal necrosis or fibrosis based on 
histopathological analysis. Moreover, SM induced steatosis did not show any zone 
specific pattern in liver histology, which further suggests that SM may be inducing the 
conversion of carbohydrates to fat rather than glycogen. 
Since the control diet (AIN93) was used to prepare SM and WBM supplemented diets, 
and none of the mice fed with WBM diet developed signs of fatty liver, our data suggest 




fatty liver.  It has been previously shown that SM has a high concentration of eritadenine, 
a compound that has a hypocholesterolemic effect (Sugiyama K &Yamakawa 1996). Rats 
fed a diet supplemented with eritadenine showed altered hepatic phospholipid 
metabolism and decrease in phophatidylcholine/ phophatidylethanolamine ratio 
(Sugiyama K et al 1995). Therefore it is possible that the eritadenine might be 
contributing for the fatty liver development in mice fed SM supplemented diets. 
Since SM is known to improve lipid profile and atherosclerosis in many animal studies 
(Sugiyama K &Yamakawa 1996, Sugiyama K et al 1995,Takashima et al 1973 
&YamadaT 2002), we hypothesized that SM might reduce the serum triglycerides by 
accumulating in them in the liver.  However, we found elevated serum triglycerides in 
mice fed SM for 6 weeks then given the control diet for 8 days. This lead to us to 
examine the SM health benefits against lipedemia and atherosclerosis. In recent years, 
Liver X receptor (LXR) agonists have emerged as promising drug candidates due to their 
role in promoting reverse cholesterol transport, promoting action for the treatment and 
prevention of atherosclerosis in animal models (Venkateswaran A et al 2000). LXR 
agonists control cholesterol homeostasis by inducing ABCA1 (ATP-binding cassette) 
cholesterol efflux transporter gene (Calkin AC et al 2010).  Moreover, LXR agonists 
have been shown to have exibit anti-inflammatory effect on rheumatoid arthritis animal 
model (Park MC et al 2010). We also observed and reported the anti-inflammatory effect 
of SM on rheumatoid arthritis animal model by reducing TNF-α (Chandra L et al 2011). 
In addition, SM induced fatty accumulation did not cause inflammatory or fibrotic 
changes in the liver histology. Taking all this information together, we hypothesize that 




mechanisms by which SM and its bioactive compound cause fatty liver are under 
investigation. 
Based on our experiment, it is evident that 5% SM supplementation can lead to simple 
reversible fatty liver under isocaloric and low fat diet. In this study we used 5% SM 
fortification instead of 2% (which is close to the normal fresh mushroom consumption in 
humans based on 2000 calories/day), because we observed SM health benefits on arthritis 
animal model at this dose in our earlier study (Chandra L et al 2011). Moreover, SM is 
often being used as dried powder in the form of soup rather than whole mushroom, which 
contains 90% water content, leading to high dietary intake. Further, high dose of SM 
supplement is used in complementary and alternative medicine therapy to treat cancer 
patients (Boon H et al 2010). 
Since non-alcoholic fatty liver disease (NAFLD) has emerged as a major public health 
problem, our in-vivo observation that SM induced fatty liver has public health 
importance. There are the two main histological patterns being described in non-alcoholic 
fatty liver disease namely simple fatty liver and steato-hepatitis (NASH) (James E et al 
2010). Unlike simple fatty liver, NASH is the silent killer disease that can lead to 
cirrhosis and end stage liver failure (James E et al 2010). Invasive procedures such as 
biopsy and liver histology are required to differentiate simple liver disease from NASH. 
In our study supplementation SM caused simple fatty liver not NASH.  
In summary, the main findings of the current study are: (I) an increase in liver fat content 
in mice fed SM supplemented diet, but not WBM supplemented diet; (II) a resolution of 




on hepatic inflammation. Determining the mechanism of increased fat liver content and 
mild-to-moderate reduction of glycogen is the focus of our next studies. 
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Table 1: Composition of study diets 
Ingredients; gram/kg  Control diet  5 % SM 
fortified 
5 % WBM 
fortified 
Casein  200  200  200  
DL-methionine  3  3  3  
Sucrose  499.99  450  450  
Corn starch  150  150  150  
Corn oil  50  50  50  
Fiber (cellulose)  50  50  50  
Mineral mix  35  35  35  
Vitamin mix  10  10  10  
Choline bitartarte  2  2  2  
Ethoxyguin  0.01  0.01  0.01  
Mushroom powder  0  50 g 50 g  
Aflatoxin 0 ppb 0 ppb 0.3 ppb 






Table 2: Effect of different diet on body weight, food intake, liver weight and 
liver weight to body weight ratio. 
Measurement Control (AIN76) 
diet  
5 % SM- fortified 
diet 
 5 % WBM 
fortified 
Body weight, g 21.58±1.22
 
 20.28±1.71  21.57±1.68  
Liver, mg 1088.91±135.34  1032.09±134.24  1087.11±145.11  
Relative liver 
weight mg/g body 
weight 
49.86±4.56  50.90±5.04  50.12±5.26  
Kidney, mg 266.13±37.59
 
 253.17±42.27 267.84±18.77 
Relative kidney 
weight, mg/g body 
weight 
12.31±1.33 12.45±1.81 12.40±1.12 
Heart, mg 119.29±23.40 111.68±25.69  95.22±29.48  
Relative heart 
weight, mg/g body 
weight 
5.53±1.02 5.51±1.24 4.40±1.25  
Food intake, g/day 4.64±0.32  4.8±0.33 4.7±0.30 
 
Values are mean ± SEM; n = 12 (Study 1 only). No significant differences 




Fig. 1. Effect of control, SM and WBM supplemented diet on liver histology (H&E- A, B 
& C) and histochemistry (PAS- D, E & F and Trichrome staining- G, H & I) (imges 
representative of the each dietary treatment group under 20x magnification placed as 
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Fig. 2.  Effect  of control, SM and WBM supplemented diet on fatty liver scores in 
C57BL/6 mice. Values are means ± SEM; n = 7-9. Bars followed by different superscript 








Fig. 3.  Effect of SM withdrawal from the diet showing liver histology (H&E A-SM diet, 
B-8 days post withdrawal & C-8 days post withdrawal) and effect SM supplemented diet 
showing normal heart (H&E D, E & F) and Kidney histology (H&E G, H & I) (imges 
representative of the each dietary treatment group under 20x magnification placed as 













A B C 








Fig.  4.  Effect of Shiitake mushroom on serum triglycerides. Values are mean ± SEM; n 
= 6-7/group. Time 1=  6 weeks of feeding either the AIN93 or shiitake mushroom- 
fortified (SM) diets; Time 2 = mice fed SM diet then given the AIN93 diet for 8 days; 
Time = mice fed SM diet then given AIN93 diet for 15 days. Bars followed by different 
super-script letters or signs are significantly different; a >b; p <0.05, Shiitake versus 
AIN93 diet; † AIN93 at time 3 compared to time 1, p <0.05; ¶ SM at time 2 & 3 
















In our study-1, all mice fed with mushroom diets for six weeks showed an increase in the 
plasma IL-23, IL-6, colon MPO, colon IL-6, and inflammation score when challenged 
with 3% DSS. Although all mushroom up-regulated IL-23, PM up-regulated IL-23 
secretion on the 3rd day of in-vitro treatment and mice without DSS challenge unlike 
other mushrooms. These findings suggest mushroom supplementation promotes IL-
23/IL-17 axis in improving gut immunity against certain GI pathogens. Our in-vitro 
findings indicate the Dectin-1 pathway is the major pathway in WBM and PM induced 
IL-23 production. Difference in the IL-23 secretion response among these mushrooms 
was observed in both in-vitro and in-vivo models. This difference could partly be 
explained by the mushrooms action on Dectin-1 pathway.  
In our study-2, mice fed the SM diet developed fatty liver unlike mice fed the AIN93 and 
WBM diets. This study suggests the observed difference in the fatty liver development 
among mushrooms could be due to their mechanism of action on fatty acid metabolism. 




steatosis was resolved within two weeks of stopping SM diet. In addition, SM induced 







Recommendations for future research 
Study-1: 
Future research should be directed to evaluate the protective effect of WBM & PM on 
animal models of GI infectious diseases such Salmonellosis, Campylobacteriosis, E. coli 
infections, listeriosis, and Cholera. Studies investigating the immunostimulatory effects 
of WBM & PM on oral mucosal vaccines could be an exciting area of future research. 
Considering mushroom consumption patterns among humans such as average weekly 
consumption, frequency of consumption, realistic animal studies using 2% or less 
mushroom supplementation with 2-3 times per week are warranted . More mechanistic 
studies using primary dendritic cells and genetically modified mice might be useful to 
establish the molecular targets for these mushrooms.   
Study-2: 
Future studies should be directed to investigate how these SM caused fatty liver by using 
hepatocyte cell lines. Studies looking at the dose and time response of SM in fatty liver 
development are also needed. Future research should also be focused to investigate the 
effect of SM on high fat diet induced fatty liver animal models. Human studies evaluating 
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Scope and Method of Study:  
The Gastro Intestinal (GI) tract represents the largest mucosal surface in the body responsible for 
digestion, absorption of essential nutrients and protection against various pathogens entering 
through GI tract. Dendritic cells (DCs) in the GI tract plays major role in gut immune response 
through capturing and transferring antigens to T-cells and releasing cytokines. Although several 
cytokines produced by DCs are involved in gut immunity, IL-23 is involved in the defense 
against most pathogens in the GI tract through up-regulation of defensins. Previous report from 
our lab showed that the extracts from edible mushroom enhance α-defensin production in in-vitro 
cell line The aim of this study was to investigate  effect of white button (WM) and portabello 
(PM) mushrooms on IL-23 secretion both in-vitro and in-vivo models. We also assessed the side 
effects of these mushrooms by using histopathology. We used C57B6 mice for studying IL-23 
secretion and toxicological evaluation. We used 3% DSS to induce acute inflammation because 
DSS induced inflammation is localized to the GI tract rather than systemic inflammatory 
response. Moreover, we are interested to study the effect of mushrooms on intestinal dendritic 
cell response. We also used J.744.1 a mouse monocytic cell line to study the molecular 
mechanism by which edible mushrooms up-regulate IL-23 secretion. We used spleen cell culture 
for ex-vivo cytokine secretion assay. Cytokines were measured by using ELISA. 
Findings and Conclusions:   
In DSS untreated mice, the plasma IL-23, IL-6 levels were low compared to DSS treated mice. 
All the mice fed with mushroom diets for six weeks showed an increase in the plasma IL-23, IL-
6, colon MPO, colon IL-6, and inflammation score when they challenged with 3% DSS. Although 
all mushroom up-regulates IL-23, PM up-regulates IL-23 secretion on the 3rd of day of in-vitro 
treatment and mice without DSS challenge unlike other mushrooms. Data suggest that mushroom 
consumption may increase gut immunity and provide resistance against certain pathogens through 
up-regulation of IL-23. These findings also suggest Dectin-1 receptor pathway is the major 
pathway in WBM and PM induced IL-23 production. Difference in the IL-23 secretion response 
among these mushrooms was observed. This difference could be due to their mechanism of action 
on Dectin-1 receptor. Similarly, mice fed the SM diet developed fatty liver unlike mice fed the 
AIN93 and WBM diets. This also suggests difference in the mechanism of action of these 
mushrooms in the development of fatty liver. 
